Close menu




September 22nd, 2025 | 07:55 CEST

AJN Resources, TUI, Evotec: Fresh capital and insider purchases!

  • Mining
  • Gold
  • Commodities
  • travel
  • Biotechnology
Photo credits: pixabay.com

Fresh capital, insider purchases, or significant changes in the shareholder base can be important signals regarding future share price performance. The leverage effect of fresh capital is particularly high for smaller companies. This is because projects can be launched with manageable amounts of capital, bringing important milestones closer. However, the stock market sometimes reacts late because small or micro-caps fly under the radar of the investor community. However, it is precisely this constellation that creates good opportunities for active and vigilant investors.

time to read: 4 minutes | Author: Carsten Mainitz
ISIN: AJN RESOURCES INC. O.N. | CA00149L1058 , TUI AG NA O.N. | DE000TUAG505 , EVOTEC SE INH O.N. | DE0005664809

Table of contents:


    AJN Resources: Capital increase successfully completed!

    The exploration company AJN Resources recently completed a capital increase of CAD 470,000. The placement price per share was CAD 0.12, well above the current price of CAD 0.09. In addition, subscribers to the placement received one warrant with an exercise price of CAD 0.15 and a four-year term. The Canadian company's market capitalization is currently just under CAD 6 million.

    The Company will use the cash inflow to further develop its flagship Okote Gold project in Ethiopia. Due diligence is currently underway, with an experienced team of geologists focusing on mapping and sampling the extensive artisanal mining sites that have yet to be explored. The Company is also analyzing historical drill cores and trenches to gain a better understanding of the mineralization. Based on the findings, a drilling program will follow, which is expected to include at least 1,500 meters of diamond core drilling.

    AJN Resources owns 70% of the Okote project, which covers an area of 672 sq km and is centrally located in the Adola Gold Belt, a gold-rich area. Just 100 km away lies the Lega-Dembi mine, one of the largest gold mines in the country, with reserves of 4.5 million ounces of gold. Historical results from the previous owner indicate gold mineralization grades of up to 8.7 g/t over several meters at Okote.

    The strategic rationale is that the extent of the mineralization and the continuation of the trends and formations from the Lega-Dembi mine could be demonstrated at the largely unexplored Okote site. Such indications here could provide a substantial boost to the share price. A further goal is to prepare a NI 43-101 compliant report in the future, providing an initial resource estimate. Achieving this milestone typically enhances the valuation of exploration companies, as it allows investors to better assess the project's potential and opportunities.

    AJN Resources is led by CEO Klaus Eckhof, a seasoned veteran in the African commodities sector with decades of experience. With his expertise, extensive network, and proven track record in the development and sale of exploration companies, AJN Resources is in an excellent position. In addition, the big picture of rising gold prices speaks in favor of the Company and its stock. Currently, an ounce of the yellow metal costs just under USD 3,700.

    TUI – Promising developments! Will there be a new forecast upgrade soon?

    On Tuesday of this week, the tourism group will provide a booking update. Investors will be able to get an idea of where the Hanover-based company stands in the final quarter. TUI has a shifted fiscal year and will present its annual report on December 10. In mid-August, the Company reported its best Q3 results to date and subsequently raised its forecast for the year as a whole. On average, analysts are setting a target price of around EUR 10.80 for the stock, which would represent a potential upside of 35%.

    Several positive announcements caught the attention of investors last week. The Hanover-based company entered into a strategic partnership with Oman. TUI will thus become a key partner in the implementation of "Oman Vision 2040," according to which Oman will position itself as a sun and beach destination for European vacationers. It was also agreed that the state would become a strategic shareholder in TUI with a 1.4% stake.

    Evotec – Insider purchases give a boost

    The news that the CFO of the life sciences company acquired shares last week helped push the share price above the EUR 6 mark. Since the end of 2023, the shares have plunged from a level of over EUR 20 to around EUR 5. Reasons for this decline include insider trading by the former CEO, a change in strategy, and poor operational performance.

    In July, the Hamburg-based company shocked investors with a revenue warning, and the latest figures from mid-August also failed to convince investors. Weak demand in the area of drug discovery continues to weigh on the Company. Despite cost-cutting measures, losses widened in the first half of the year. Management continues to assert that it is on a good path to return to profitable growth. The sale of the subsidiary's biopharmaceutical production facility in France was only briefly celebrated by investors.

    Perhaps the upcoming quarterly figures, which are scheduled for November 5, will provide new impetus for the stock. Many market observers consider the Company to be undervalued with a market capitalization of EUR 1.1 billion. Analysts see upside potential of 50% within the next 12 months.

    The conditions are right

    Whether interest rates, consumption, inflation, or commodity prices, the signs point to further growth on the stock markets. The companies mentioned should benefit from this trend. TUI is performing very well, boosted by its strategic partnership with Oman. Evotec is considered undervalued and is working toward sustainable strategic changes. With its recently completed capital measure, AJN Resources can take decisive steps toward a revaluation of the micro-cap. For now, the new drilling program is the focus of investor interest.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Armin Schulz on August 12th, 2026 | 07:05 CEST

    Three Paths to the Cancer Drug of the Future: BioNTech, Vidac Pharma, and Pfizer Under the Oncology Spotlight

    • Biotechnology
    • Biotech
    • Pharma
    • Oncology

    Oncology has become the most dynamic field of innovation in the pharmaceutical industry. The focus is not on finding a miracle cure, but rather on developing highly precise, personalized therapies that target tumors at the molecular level. For investors, this market, which is growing at double-digit rates, is attractive in the long term. While there is a world of difference between established corporations and agile biotech companies with groundbreaking technology platforms, both offer enormous potential for value appreciation. Today, we take a look at three companies that are aiming to discover the next blockbuster drug: BioNTech, Vidac Pharma and Pfizer.

    Read

    Commented by Tarik Dede on August 11th, 2026 | 07:40 CEST

    Commodity Stocks on the Verge of a Breakout? First Majestic Silver, Globex Mining and B2Gold in Focus

    • Mining
    • Gold
    • Silver
    • Commodities
    • Investments
    • geopolitics

    Until recently, markets largely took it for granted that US interest rates would rise this year. But several factors now point in the opposite direction, not least Donald Trump's calls for lower rates. More importantly, the economic data is increasingly arguing against a rate hike, even though inflation remains elevated and above the Federal Reserve's target range. Most recently, it was the weak US jobs data that fueled the markets. Instead of creating new jobs, the US economy is currently seeing employment decline. For precious metals, this provided an additional boost following an already strong start to the week. Investors may therefore want to position themselves early, as the next rally in the sector could already be underway. Today, we take a closer look at First Majestic Silver, Globex Mining and B2Gold.

    Read

    Commented by Armin Schulz on August 11th, 2026 | 07:30 CEST

    Correlation Breakdown, Paper Gold Banned: Positioning for the Next Gold Rally with Newmont, Lahontan Gold, and Agnico Eagle

    • Mining
    • Gold
    • Silver
    • Nevada
    • Commodities
    • Investments

    The latest sharp rise in the price of gold has not only broken technical barriers but also shattered financial market dogma. Normally, gold prices would be expected to decline when US real yields reach new highs. This time, however, both are moving higher in tandem — a sign of waning confidence in monetary policy. Added to this is the fact that paper gold has reportedly been banned in China, potentially increasing demand for physical bullion. This could fuel the next rally in the long term. Against this backdrop, we take a closer look at industry leader Newmont, emerging gold producer Lahontan Gold, and Agnico Eagle.

    Read